Recent shortages of molybdenum-99 ( 99 Mo) have led to an examination of alternate production methods that could contribute to a more robust supply. An electron accelerator and the photoneutron reaction were used to produce 99 Mo from which technetium-99m ( 99m Tc) is extracted. SPECT images of rat anatomy obtained using the accelerator-produced 99m Tc with those obtained using 99m Tc from a commercial generator were compared. Disks of 100 Mo were irradiated with x-rays produced by a 35 MeV electron beam to generate about 1110 MBq (30 mCi) of 99 Mo per disk. After target dissolution, a NorthStar ARSII unit was used to separate the 99m Tc, which was subsequently used to tag pharmaceuticals suitable for cardiac and bone imaging. SPECT images were acquired for three rats and compared to images for the same three rats obtained using 99m Tc from a standard reactor 99 Mo generator. The efficiency of 99 Mo99m Tc separation was typically greater than 90%. This study demonstrated the delivery of 99m Tc from the end of beam to the end user of approximately 30 h. Images obtained using the heart and bone scanning agents using reactor and linac-produced 99m Tc were comparable. High-power electron accelerators are an attractive option for producing 99 Mo on a national scale.
Introduction
The most widely used isotope for medical imaging is 99m Tc. Most 99m Tc is obtained from the decay of 99 Mo, which is produced as a fission product from irradiating highly enriched uranium (HEU) in a research reactor. The unexpected shutdown of the NRU reactor in Canada in 2009 led to a significant, world-wide shortage of 99 Mo and a renewed emphasis on establishing additional supplies (Nathwani and Wallace 2010) . Although research reactors have served as a robust supply of 99 Mo for many years, security concerns related to HEU have led to efforts to eliminate its use for the production of medical isotopes (NRC (US) 2009). Thus, in addition to considering new fission sources of 99 Mo, there has been considerable interest in alternative production techniques that do not require any uranium.
Although there are several possible reaction channels that might be used, two have been investigated in considerable detail. If protons with energies between 10 and 25 MeV are used to irradiate a target of 100 Mo, the most prominent reaction channel is 100 Mo (p, 2n) 99m Tc (Celler et al 2011) . This suggests that a small cyclotron, typical of those used to produce PET isotopes, could also be used to produce 99m Tc (Guérin et al 2010) . Because 99m Tc (6 h half-life) is produced directly, one is not able to benefit from the long half-life (66 h) of 99 Mo and thus the cyclotron approach is a local solution and will require a distributed network of machines.
The second reaction channel uses high-energy photons and the reaction 100 Mo (γ , n) 99 Mo (Bennett et al 1999) . The photoneutron absorption cross section has a broad maximum centered at about 14 MeV. In this case, a linear electron accelerator is used to produce a high-energy photon beam, via the bremsstrahlung process (Ross et al 2010) . Linear electron accelerators (linacs), with beam powers of 50 kW or more, have been developed for the radiation processing industry. Estimates indicate that two linacs, operating at a beam energy of about 35 MeV, could produce all of Canada's requirements for 99 Mo and at a cost less than fission 99 Mo. Because 99 Mo produced by a linac is formed within a target of considerable mass, the activity per unit mass, or specific activity, is much lower than is the case for 99 Mo produced by fission. This means that the standard alumina column that is used for separating 99m Tc from 99 Mo cannot be used for linac- 99 Mo. This problem has been studied in the past and several processes such as sublimation separation (Bennett et al 1999) and methyl ethyl ketone (Narasimhan and Mani 1976) have been developed. Although all have met with some measure of success, most have one or more limitations, such as poor separation efficiency, the need for special laboratory conditions or highly trained staff, the use of hazardous chemicals or the lack of easy automation. The separation process based on the aqueous biphasic extraction chromatography (ABEC) column (Rogers et al 1997) and implemented in the ARSII separator (McAlister and Horwitz 2009) has eliminated all these limitations and provides automated separation of 99m Tc from a solution containing low specific activity 99 Mo. This process also creates almost no waste. Bennett et al showed that while 94 Nb is a contaminant that can be produced through this process, the amount of this potential waste is very small or about 370 Bq (10 nCi) per production cycle.
Our objective in this study was to compare 99m Tc generated from 99 Mo produced by a linear electron accelerator (linac99m Tc) to commercially available 99m Tc generated from 99 Mo produced in a fission reactor (fission99m Tc). The linac99m Tc was created using the National Research Council (NRC) 35 MeV electron accelerator and the ARSII separator developed by NorthStar Medical Radioisotopes. In this work, we describe and evaluate each of the steps leading to a product containing about 1110 MBq (30 mCi) of sodium pertechnetate (NaTcO 4 ) in 5 mL of saline solution. Finally, we compare the SPECT images acquired in vivo in rats using linac99m Tc and fission99m Tc formulated into two of the more commonly used tracers: cardiac images using tetrofosmin and bone images using methylene diphosphonate (MDP).
Materials and methods

Irradiations
The NRC electron accelerator was used to generate a 35 MeV electron beam with a beam power of 1.8 kW. The electrons impinged on a fully stopping, water-cooled tungsten target.
The resulting x-ray beam irradiated one or more air-cooled molybdenum disks, 1 mm thick and 10 mm in diameter. Each disk was formed by pressing and sintering metal powder. The powder was purchased from Isoflex USA with a certificate of analysis indicating that the enrichment was greater than 99% in 100 Mo (Isoflex USA 2011) . The powder contained the other natural isotopes of molybdenum at levels less than 0.1% with the exception of 98 Mo which was present at the level of 0.55%. All other trace elements were analyzed to be much less than 5 ppm with the exception of Si and Zn which were present at levels of 20 and 10 ppm, respectively. The 0.5 g disks were irradiated for about 10 h to produce a 99 Mo activity of approximately 1110 MBq (30 mCi) per disk.
Dissolution
The irradiated disks were dissolved over a period of about 2 h using 30% hydrogen peroxide (H 2 O 2 ), forming an acidic solution of molybdenum trioxide (MoO 3 ). The rate of dissolution was controlled by lowering the temperature and minimizing the amount of H 2 O 2 used. Sodium hydroxide (NaOH) tablets were added to the solution, forming a 5 M solution of NaOH with a volume of about 25 mL. The resulting sodium molybdate (Na 2 MoO 4 ) solution was then heated at a temperature greater than 80
• C for 2 h in order to promote the breakdown of any residual H 2 O 2 .
Separation
99m Tc was separated from the solution using the NorthStar automated radionuclide separator (ARSII (McAlister and Horwitz 2009)). The key element of the separator is a column containing an (ABEC (Rogers et al 1997) ) resin which selectively retains technetium. The automated separation cycle, which takes about 45 min, passes the parent solution over the column and then rinses the retained technetium into a product vial using about 5 mL of normal saline solution. The separation efficiency of the ARSII was obtained using γ -ray spectroscopy and ionization chamber measurements.
Three different elution chemistries were used in this study. They are described in detail in section 3.1.
Tracer compounding
For the two tracers used in this study, 99m Tc, from both fission and accelerator sources, was attached to the pharmaceutical using standard commercial kits and following the procedures recommended for use of these kits. For the tetrofosmin studies, we used a Myoview kit (DraxImage) and for the MDP studies, we used a Medronate kit (DraxImage).
Product assessment
Several additional quality control (QC) tests were carried out with a view to demonstrate that the 99m Tc product solution met the USP (and Health Canada) (USP 2007) regulatory requirements for fission99m Tc. The tests were performed in the same manner used to assess fission99m Tc and are summarized in the following list.
• Eluate acidity. The pH of the sodium pertechnetate was measured using a pH paper with the full range of 0-14.
• Aluminum breakthrough. A colorimetric aluminum spot test was carried out using chromatography strips for aluminum breakthrough. This check is performed because the final step of the eluted 99m Tc in the ARSII is to pass through an alumina column which acts as a guard to scavenge any molybdenum that has remained on the primary separation column. This is completely analogous to the final stage of 99m Tc production using a standard reactor-based 99m Tc generator.
• Radionuclide purity. The radiopurity of the product was evaluated using a germanium γ -ray spectrometer immediately after the separation which is 24 h after the end of beam.
No isotopes were observed in the spectrum other than 99m Tc. An upper limit on the amount of 99 Mo breakthrough was estimated to be less than 1.5 × 10 −5 Bq of 99 Mo per Bq of 99m Tc at the 95% confidence level, which is an order of magnitude better than the existing requirements. In addition, a 99 Mo assay was performed using a Capintec CRC-35R ion chamber to confirm that the 99 Mo breakthrough level was acceptable.
• Radiochemical purity. The radiochemical purity of the NaTcO 4 was evaluated using instant thin layer chromatography (iTLC) strips with silica gel (SG) as the stationary phase and acetone as the mobile phase. Additional QC was performed on the tagged radiopharmaceutical. As previously mentioned, two pharmaceuticals were used in this study. The first was tetrofosmin which is commonly used for cardiac perfusion studies and the second was MDP which is a common tracer for bone imaging. The following list summarizes the additional tests performed on the constituted pharmaceutical.
• The pH of the tagged radiopharmaceutical was determined using the pH paper with an appropriate range required by the QC for the pharmaceutical.
• The radiochemical purity of the tagged radiopharmaceutical was evaluated using iTLC-SG chromatography strips.
-The mobile phase for the 99m Tc-tetrofosmin was a 35:65 v/v mixture of acetone and dichloromethane.
-Two separate chromatography strips were required to determine the radiochemical purity of 99m Tc-MDP. A mobile phase of 0.9% sodium chloride or standard saline was used to determine the percentage of reduced TcO 2 in the injection. A mobile phase of acetone was used to determine the percentage of free TcO − 4 in the injection. The remaining percentage determined the radiochemical purity of the final injection.
Representative samples of inactive separations of the tagged pharmaceutical were checked at NRC for sterility and pyrogen content. The tests performed are described below and all representative samples passed the sterility and pyrogen tests.
• Sterility. The product was plated on brain heart infusion agar and chocolate agars and observed for growth for 96 h. No growth was observed.
• Pyrogen content. The product was tested for the existence of pyrogens using the limulus amebocyte lysate test or the bacterial endotoxin test and found to have less than 0.125 endotoxin units per milliliter.
Animal model: rats
White male Sprague-Dawley rats were used in these experiments. The rats were between six and seven weeks old at the start of the study and similar in size with an average body weight of 252 ± 9 g. The rats were handled using standard methods and the approval for the study was obtained from the Animal Care Ethics Committee of the University of Ottawa.
SPECT imaging
For the tetrofosmin study, a group of three male rats were imaged consecutively using the three different formulations of the tracer. Images were first obtained with fission99m Tc-tetrofosmin, followed two days later by linac99m Tc-tetrofosmin images (buffer) and then one day later by linac99m Tc-tetrofosmin images (no buffer). The images for the linac99m Tc-MDP (buffer) were acquired prior to the development of the bufferless protocol and so were acquired in a separate set of animals from the linac99m Tc-MDP (no-buffer) images. One group of three male rats were imaged with fission99m Tc-MDP and then imaging was repeated three days later with linac99m Tc-MDP (buffer). A separate group of three male rats were imaged with fission99m Tc-MDP and then imaging was repeated three days later with linac99m Tc-MDP (no buffer).
All images were acquired using a four-head NanoSPECT/CT small-animal scanner (Bioscan). Data were obtained with nine-pinhole collimators on each detector head with 2.5 mm pinhole apertures. For the cardiac study, 79 ± 6 MBq (2.2 ± 0.2 mCi) of 99m Tctetrofosmin was injected (calibrated to the start time of the first scan). Imaging was started 30 min following the tracer injection. Four consecutive 10 min acquisitions of the heart (48 projections, 90
• rotation) were then acquired over a 45 min period. For the bone study, 83 ± 11 MBq (2.3 ± 0.3 mCi) of 99m Tc-MDP was injected and imaging began 90 min postinjection. The buffer images were obtained as two acquisitions with abutting fields of view (48 projections, 90
• rotation, 12 min duration), one acquired immediately following the other. Three sets of acquisitions were obtained over a 90 min period. For the no-buffer images, a single whole body acquisition was obtained (64 projections, 135
• rotation, 15 min duration). These scans were repeated five times over a 90 min period.
All images were reconstructed using an ordered-subset expectation-maximization (OSEM) iterative algorithm (Schramm et al 2003) , that was supplied by the vendor, into an isotropic voxel size of 0.6 mm. We used 24 iterations (8 iterations × 6 subsets, 8 iterations × 4 subsets, 8 iterations × 3 subsets) followed after each iteration by smoothing with a 3D Gaussian filter of 0.63 mm FWHM. Images were then exported off-line for the analysis with in-house software.
SPECT analysis
The images were visually compared qualitatively and were also analyzed quantitatively. For the tetrofosmin studies, a volume of interest (VOI) was defined that encompassed the heart and the threshold was set to the level of the background activity. The total number of reconstructed counts in the VOI was then corrected for the physical decay of the isotope and normalized to the total injected activity. The count density was calculated as the total counts divided by the total volume. A similar VOI was defined around the liver. The total number of counts in the heart and the ratio of count density in the heart to that in the liver were compared over the five scans, the three rats and the three different tracer formulations. Differences in the mean values were assessed using the Wilcoxon signed-rank non-parametric test with p < 0.05 considered significant.
For the MDP studies, a bone VOI was created including all bone voxels with activity above background. From this VOI, the total counts and count density were determined. The liver was again chosen as a reference organ and uptake and count density within this VOI were also calculated. These values were then corrected for the physical decay of the isotope and differences in acquisition times and then normalized with respect to the injected dose of tracer. The total bone counts and the ratio of the bone/liver count density were compared for the different tracers, rats and scans. Differences in the mean values were assessed using the Wilcoxon signed-rank non-parametric test for the comparison of repeated scans within the same group of animals and a Mann-Whitney (Wilcoxon rank-sum) non-parametric test was used for independent samples for comparisons between separate groups. The result was considered significant if p < 0.05.
Results
Elution chemistry
The ARSII elution chemistry originally called for the use of a gluconate buffer to adjust the pH of the ABEC column after it is loaded with 99m Tc. When performing the scan with this source of 99m Tc tagged to the heart scanning agent, tetrofosmin, the images were clean and virtually indistinguishable from those of the reactor 99m Tc. However, when the same procedure was performed with the MDP scanning agent, the rats displayed uptake in the cortex of the kidney (see figure 1) . While the bone uptake was still good for diagnostic purposes, the reason for the kidney uptake was investigated further. Both the tetrofosmin and MDP QC radiochemistry tests passed.
A sample of the tagged pharmaceutical was measured using high-performance liquid chromatography and it was determined that there was gluconate in the tagged pharmaceutical that was on the order of 2 mg mL −1 , making it comparable to the amount of active ingredient in a given pharmaceutical kit. The pharmaceuticals are designed to take the sodium pertechnetate in which 99m Tc is in the +VII oxidation state and through a reducing agent (in this case stannous chloride) reduce the oxidation state to the appropriate level of the active ingredient. Gluconate in itself can tag to 99m Tc in the +V oxidation state. Gluconate is contained in the formulation of the tetrofosmin kit and its role is as a placeholder for 99m Tc (V) before transferring it to the tetrofosmin which also tags to 99m Tc (V). Therefore, the extra gluconate impurity that ended up in the formulation would not be expected to affect the performance of the pharmaceutical.
On the other hand, MDP tags to 99m Tc in the +IV oxidation state. In this case, the gluconate impurity removes some of 99m Tc (V) from the process of reduction and, having no competition for that chemical species, remains in that form. The QC tests for MDP are not designed to detect this subtle difference and hence both labeled complexes traveled together in the iTLC strips.
We hypothesized that 99m Tc-gluconate was then metabolized by the kidneys of the rat and observed in the cortex. This hypothesis was confirmed by spiking a reactor 99m Tc control with the same level of gluconate impurity. The resulting images showed a similar level of kidney uptake. This test confirmed that the source of the radioisotope was not the cause of the anomalous uptake seen in the kidneys.
As a result of these observations, two different approaches were taken to alter the ARSII elution chemistry. The first approach was to replace the gluconate buffer with an acetate buffer which was deemed to be a more suitable biocompatible solution to use. In the second approach, the buffer was removed altogether and the pH adjustment was performed by the use of ion exchange resins thereby removing the possibility of the buffer ending up in the product. When comparing to the fission99m Tc, we considered both elution protocols for generating the linac99m Tc: the acetate buffer rinse (buffer) and the second protocol without a buffer rinse (no buffer).
All the tabulated results and analyses are shown for the same three rats with the exception of those rats used for the buffer rinse MDP. The buffer MDP rats were different as these scans were performed before the bufferless protocol was developed. However, rats for this study were of similar age and body weight as those used in all other runs.
Product characteristics
All the QC performed met or exceeded the requirements outlined in the existing USP. Tables 1  and 2 indicate the QC results of the pertechnetate used as the parent to the pharmaceutical kits. The parent NaTcO 4 provided by a linac was always of high quality. The fission99m Tc which was ordered directly from the nuclear pharmacy was not tested for QC but assumed to be of suitable quality for tagging to pharmaceuticals. While separation efficiency of the ARSII was not the object of this study, nevertheless, it was estimated to be between 88% and 94% for each of the standard buffer runs used in this study. This is comparable to published results of ABEC in Dale et al (2010) . The efficiency for no-buffer runs was lower, mainly due to the non-standard configuration required to perform this separation on the ARSII infrastructure. In particular, there was an extremely low extraction efficiency of 30% for the active run used in the MDP no-buffer run. This was an isolated event in which 99m Tc was not fully loaded onto the ABEC column. Nevertheless, a sufficient amount of 99m Tc was supplied for the study. Table 3 shows the QC for the tagged 99m Tc-tetrofosmin pharmaceutical. The pH was measured using pH paper with a resolution of ±0.5. Therefore while some of the runs had a recorded pH outside the criterion for tetrofosmin, it was considered a pass within the uncertainty of the measurement tool. In addition, the rats showed no adverse effects to these injections.
Tetrofosmin: heart imaging agent
Example images for one of the rats with all three tracer formulations are shown in figure 2. The images show good uptake in the heart for all three tracers but with the appearance of a small increase in liver uptake for the buffer linac99m Tc tracer. The normalized uptake in the heart, corrected for the decay of 99m Tc, is shown in figure 3 . The uptake shows a similar pattern over time and neither of the linac99m Tc formulations are significantly less than the fission99m Tc. The heart/liver uptake ratio for the three formulations is shown in figure 4 . There is no significant difference between the no-buffer linac99m Tc and the fission99m Tc (p = 0.97), but the buffer linac99m Tc ratio is significantly less than both the fission99m Tc and the no-buffer linac99m Tc (p < 0.01 for both). These results support the visual assessment of a small increase in liver uptake for the linac99m Tc generated using the acetate buffer approach. Nevertheless, both linac99m Tc tracers produce clinically acceptable heart to background ratios. The trends in figures 3 and 4 indicate the biological clearance of the pharmaceutical. Table 4 shows the QC for the tagged 99m Tc-MDP pharmaceutical. Example images for one of the rats with all three tracer formulations are shown in figure 5 . The images show good uptake in the skeleton for all three tracers. Some uptake is observed in the pelvis of the kidney. This uptake was observed with three tracers in similar amounts and (a) (b) (c) Figure 2 . SPECT images of a rat injected with fission-99m Tc-tetrofosmin (control) (a), linac99m Tc-tetrofosmin using an acetate buffer rinse (buffer) (b) and linac-99m Tc-tetrofosmin without any buffer rinse (no buffer) (c). Figure 3 . Uptake in the rat myocardium with tetrofosmin SPECT using fission-99m Tc (control), linac-99m Tc with an acetate buffer (buffer) and linac-99m Tc without a buffer (no buffer). Total counts in the heart are normalized with respect to the injected activity and corrected for the physical decay of 99m Tc. The error bars express the range in values over the three rats.
MDP: bone imaging agent
was not consistently associated with a specific rat or tracer formulation. The degree of kidney uptake, if observed in human patients, would be clinically acceptable.
It was observed that the uptake of rat 1 with the no-buffer linac99m Tc had much lower bone uptake than the other two animals imaged on that day. We observed no visual difference between the animals and noted that the total number of counts in the field of view was similarly reduced. The total counts averaged 2.8 standard deviations below the mean of the total counts from the combination of the control images taken three days earlier and other no-buffer images acquired that day. The ratio of bone/total counts (figure 6) of the three no-buffer images is very consistent. These observations suggest that there was an error in the injection, most likely a failure to flush the line with saline resulting in a portion of the injected activity remaining in the catheter. To compensate for this, the total counts for rat 1 were rescaled by 1/0.57 to match the average total counts in rats 2 and 3 obtained that day with the same tracer formulation.
The total bone uptake corrected for the physical decay of the isotope and normalized for the total injected activity is shown in figure 7 . Neither of the linac99m Tc formulations had . The ratio of uptake in the rat myocardium to uptake in the liver for tetrofosmin SPECT using fission-99m Tc (control), linac-99m Tc with an acetate buffer (buffer) and linac-99m Tc without a buffer (no buffer). The error bars express the range in values for the three rats. significantly lower bone uptake than the fission99m Tc formulation. The bone/liver ratio was also compared (figure 8). The bone/liver ratio for the fission99m Tc tracer was not significantly different from the no-buffer linac99m Tc (p = 0.25). While there was a trend that was consistent with the tetrofosmin results suggesting an increased uptake in the liver with the buffer linac99m Tc as compared to the bufferless linac99m Tc, this was not significant (p = 0.20).
Discussion
One of the advantages of the scheme described in this paper is that there would be a seamless transition to the new source of 99m Tc. Like the existing fission99m Tc generator, the separation . The ratio of uptake in the bone to the total uptake within the field of view for images of the three rats acquired with MDP SPECT using linac-99m Tc without a buffer. Although the total number of counts for rat 1 was only 57% that of the other two rats, the ratio of bone/total counts is very similar. . Uptake in the rat skeleton with MDP SPECT using fission-99m Tc (control), linac-99m Tc with an acetate buffer (buffer) and linac-99m Tc without a buffer (no buffer). Total counts in the bones are normalized with respect to the injected activity and corrected for the physical decay of 99m Tc. The error bars express the range in values for the three rats. Figure 8 . The ratio of uptake in the bone to uptake in the liver for MDP SPECT using fission-99m Tc (control), linac-99m Tc with an acetate buffer (buffer) and linac-99m Tc without a buffer (no buffer). The error bars express the range in values for the three rats. scheme described here operates at room temperature and atmospheric pressure. However, unlike the existing supply chain, the hospitals and nuclear pharmacies would receive deliveries of 99 Mo99m Tc in solution to be separated in an automated device located on site rather than receiving 99 Mo99m Tc together in a single generator. The separator would remain at the location of 99m Tc production with a footprint comparable to that of a small microwave oven. Another advantage of this separation model, that is transparent to the end users of 99m Tc, would be that the isotope can be delivered directly from the production site to the hospital or nuclear pharmacy. This is in contrast to the fission generator production process which typically takes about one week. The shorter delivery time of about 24 h translates into a more efficient use of the initial supply of 99 Mo. Finally, after a fission99m Tc generator has been spent to the point at which it no longer contains clinically relevant quantities of 99m Tc, it is returned for refurbishing. In the linac-produced 99m Tc scenario, the separator is located at the hospital or nuclear pharmacy and only the solution is transported and hence multiple spent solutions could be ganged together to extract usable amounts of 99m Tc or even single doses. This possibility further improves the efficient use of the available 99 Mo99m Tc supply.
Conclusions
High-power electron accelerators are an attractive option for producing 99 Mo on a national scale. The process requires no uranium, generates almost no waste, can be implemented on a short timescale and is economically competitive with 99 Mo produced by reactors. This work shows that 99m Tc derived from accelerator-produced 99 Mo using the ARSII separator or similar technology has properties similar to that obtained from standard 99m Tc generators and produces high-quality SPECT images of myocardial perfusion (with tetrofosmin) and skeletal osteoblastic activity (with MDP) in rats. The absolute per cent uptake and target-tobackground ratios were found to be at least equal to those obtained with 99m Tc generated from fission-produced 99 Mo.
